Publications by authors named "Seneca R Oxendine"
Article Synopsis
- Serum autoantibodies against the nicotinic acetylcholine receptor (AChR) in autoimmune myasthenia gravis (MG) can cause damage through complement activation, receptor blockade, and antigenic modulation.
- Researchers created a library of human-derived monoclonal antibodies (mAb) to understand how these mechanisms function and found that some mAbs can perform more than one pathological role.
- The study indicates that treatment strategies should be reconsidered, as some autoantibodies can interact through multiple pathways, potentially undermining therapies targeting a single mechanism.
Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA).
View Article and Find Full Text PDF